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consultant to Bostrecent years, athletic participation has more than doubled in all major demographic groups, while simultaneously,
children and adults with established heart disease desire participation in sports and exercise. Despite conferring
favorable long-term effects on well-being and survival, exercise can be associated with risk of adverse events in the
short term. Complex individual cardiovascular (CV) demands and adaptations imposed by exercise present distinct
challenges to the cardiologist asked to evaluate athletes. Here, we describe the evolution of sports and exercise
cardiology as a unique discipline within the continuum of CV specialties, provide the rationale for tailoring of CV care
to athletes and exercising individuals, deﬁne the role of the CV specialist within the athlete care team, and lay the
foundation for the development of Sports and Exercise Cardiology in the United States. In 2011, the American
College of Cardiology launched the Section of Sports and Exercise Cardiology. Membership has grown from 150 to
over 4,000 members in just 2 short years, indicating marked interest from the CV community to advance the
integration of sports and exercise cardiology into mainstream CV care. Although the current athlete CV care model
has distinct limitations, here, we have outlined a new paradigm of care for the American athlete and exercising
individual. By practicing and promoting this new paradigm, we believe we will enhance the CV care of athletes of all
ages, and serve the greater athletic community and our nation as a whole, by allowing safest participation in sports
and physical activity for all individuals who seek this lifestyle. (J Am Coll Cardiol 2014;63:1461–72) ª 2014 by
the American College of Cardiology FoundationConﬁrmation of the beneﬁts of exercise (1–4), increased
participation in organized athletics, and efforts to combat
the obesity epidemic have led to marked increases in the
numbers of Americans participating in sports and exercise
in all major demographic groups over the last decade (5–9).
Among athletes 35 years of age, 44 million youth (18
years of age) participate annually in organized sports, with
7.7 million and 463,202 engaged at the high school and
collegiate levels, respectively (6,7). Older, or master, athletes
(35 years of age), are particularly drawn to endurance
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pation in sports and exercise (10).
Paradoxically, despite its favorable effects on well-being
and survival, exercise can acutely increase the risk of
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1462complex cardiovascular (CV) de-
mands and adaptations imposed by
exercise pose distinct challenges to
the cardiologist asked to evaluate
athletes (22,23) and/or prescribe a
level of participation (24). From
cardiac screening to resuscitation,
we propose that effective CV care
of athletes and active individuals
requires: 1) commitment topatient-
centered care; 2) an athlete-
centered CV knowledge base;
3) clinical tools grounded in the
fundamentals of sports and exercise
cardiology; 4) relevant cardiology
practice; 5) familiarity with the
“athlete healthcare delivery system”;
6) willingness to promote research
efforts; and 7) desire to advocate
for the athlete and exercising in-
dividual. Here, we provide therationale for tailoring of CV care to athletes and exercising
individuals, deﬁne the role of the CV specialist within the
athlete healthcare team, and lay the foundation for the
development of sports and exercise cardiology in the United
States.Athletes and Exercising Individuals as
Unique Cardiac Patients
Evolution of sports cardiology and the athlete as a
patient. Athletes are held in high esteem in society, owing
to their extraordinary abilities and the excessive adulation
bestowed upon them (i.e., “hero-worship”) (25). Impor-
tantly, clinicians caring for athletes have identiﬁed a distinct
set of athlete-related medical issues involving virtually every
organ system, while recognizing the potential for interaction
between medical conditions and sports performance, and the
need to make immediate and long-term “return-to-play”
(RTP) decisions (26). Such observations and practices led
to the creation of a general sports medicine specialty (27),
subspecialty interest groups such as sports podiatry (28)
and sports neurology (29), and certiﬁcations and fellow-
ships based upon a particular sport or activity, such as the
Undersea and Hyperbaric Medicine Certiﬁcation (30) and
Wilderness Medicine Fellowship (31).
Given the CV demands of exercise (32), training-related
CV adaptations (33), and the interaction of the heart with
internal and external athletic environments (34,35), sports
and exercise cardiology is a natural and obvious step in the
evolution of the sports medicine subspecialties. One of the
major components of any effective healthcare system is
“patient-centered care,” deﬁned as care “respectful of and
responsive to individual patient preferences, needs, and
values” (36). In 2012, the American College of Cardiology
Foundation (ACCF) Clinical Quality Committee proposedthe development of “patient-centered CV care” (37); as
the epitome of such care, “athlete-centered CV care” (sports
and exercise cardiology) is strongly aligned with the ACCF
proposal.Moreover, fundamental to the practice of sports and
exercise cardiology is the notion that athletes are “different”
from the general population from a physiologic and/or
medical perspective; there is also distinct heterogeneity
among athletic populations.
Epidemiology of SCD in athletes. Contrary to expecta-
tion, when considering exercise as a trigger to SCD, the
contemporary incidence of SCD is actually similar or lower
in young athletes compared with nonathletes (20). Among
American populations (age 11 to 19 years), the overall inci-
dence of SCD appears to be markedly lower in young athletes
compared with nonathletes: 0.44 per 100,000 person-years
(38) or less (39) versus 6.37 per 100,000 person-years,
respectively (40). However, SCD may be higher, 2.28 per
100,000 athlete-years, in the overall American National
Collegiate Athletic Association (NCAA) population, or even
higher in subgroups such as African Americans or male
Division I basketball players (41), suggesting that there is
variable risk according to age, sex, ethnicity, level of play, and
sport.
Prevalence of SCA among older athletes, examined largely
as a function of sport type, is reported to be 0.54 per 100,000
person-years among marathon and half-marathon partici-
pants (N ¼ 10.9 million) (42), with a 29% resuscitation rate
and resultant SCD prevalence of 0.39 per 100,000 person-
years (42). Among triathletes, SCD risk may be slightly
higher due to risks associated with open water swimming
(43). Such information can be used to answer important
questions related to the sport-speciﬁc risk of participation,
event preparation, allocation of resources, and clinical trial
design (42,44).
Athletic adaptations and cardiac testing. Brieﬂy, endur-
ance training (e.g., long-distance running) causes sustained
volume load to the heart (45), resulting in 4-chamber
enlargement and increased stroke volume at rest and exer-
cise (46). By contrast, strength training (e.g., weight lifting)
causes a pressure load to the heart (45) accompanied by
normal left ventricular (LV) wall thickness (<1.2 cm), but a
disproportionate increase in relation to cavity size (47–49).
Some sports, such as basketball, present a combination of
the 2 types of loads. For further study, readers are referred to
several excellent reviews of CV exercise physiology, training
adaptations, and interaction of the heart with the athletic
environment (22,33–35,46,47,50,51).
Training-related electrophysiological (EP) adaptations,
which appear on the electrocardiogram (ECG) in the form
of bradycardias, atrioventricular and interventricular blocks,
extrasystoles, interval prolongations, increased voltage, and
repolarization abnormalities (52), are more common in
athletes compared with nonathletes (53,54), and vary ac-
cording to sex, ethnicity, body size, and type of training
or sport (55,56). What is known about cardiac structural
athletic adaptations is shown in Table 1 (22,46–49,57–71).
Table 1
Cardiac Structural Athletic Adaptations:
35 Years of Research
1. Increases in LV and RV dimension and volume are common and more apt
to occur in endurance sports such as cycling, rowing, and cross country
skiing (46–48).
2. Increases in LV wall thickness more than 1.3 cm are unusual, but can occur in up
to 1.7% of elite athletes (46,47) and 0.4% of junior elite athletes (63).
3. Degree of adaptation varies according to sex, age, body size and mass, type of
sport, and ethnicity, especially for athletes of African descent (47,57–68).
4. A small number of healthy athletes can show 1.3- to 1.5-cm LV wall
thickness (66).
5. African athletes can demonstrate LV wall thickness up to 1.6 cm (64,67).
6. Patterns of hypertrophy vary, with endurance and strength training more likely
to cause eccentric and concentric hypertrophy, respectively (23).
7. Strength sports (weightlifting or wrestling) are associated with usually normal
thickness (<1.2 cm, but disproportionate increase in relation to cavity size)
(46–49).
8. Although uncommon among athletes in general (46), up to 11% of healthy
long-distance cyclists may have mildly reduced LVEF (68).
9. Newer techniques such as tissue Doppler and speckle tracking radial strain
echocardiography assist in differentiating physiological from pathological
remodeling (69–71).
LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; RV ¼ right ventricular.
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(63,65) and vary considerably among athlete subgroups
(57–71). Most of this work has been generated in European
or endurance athletes, with relatively little data generated
in American athletes at relevant levels of sport (high school,
collegiate, professional, masters, and recreational).
Athlete “gray zone” and differentiation from inherited
diseases. EP and structural adaptations become clinically
signiﬁcant when cardiac testing requires differentiation from
cardiac pathologies. A high prevalence of training-related
changes that mimic features of inherited diseases, accompa-
nied by what is likely low disease prevalence in athletes, can
place athletes into a unique category known as the “gray
zone” (47). Classically applied to LV cavity and wall thick-
ness (24,47), the gray zone may also apply to the RV, cor-
rected QT interval, and ST-segment. Although specialized
tools, including cardiopulmonary exercise testing, advanced
echocardiography (echo), cardiac magnetic resonance imag-
ing, supervised detraining, pharmacological infusion, and
genetic testing may be useful to differentiate between normal
adaptations and true cardiac pathology (22,24,47), to suc-
cessfully navigate gray zone nuances, CV specialists must
have a clear understanding of both the “normal” limits to
cardiac athletic adaptations and the cardinal features of the
inherited diseases that cause athlete SCD (21).
Unlikely to be the only manifestation of hypertrophic
cardiomyopathy (HCM) (72), isolated LV hypertrophy can
be seen in up to 40% of athlete ECGs (55) and is considered
a normal variant (52,73). If LV hypertrophy is accompanied
by ST-segment depression, Q waves, or left axis deviation,
HCM is far more likely, as such features are rare in athlete
ECGs (52,73,74). Given the upper limit of LV wall
thicknesses in healthy Caucasian athletes (1.3 to 1.5 cm)
(Table 1) and those of African descent (1.6 cm) (Table 1)and the overlap with HCM wall thickness, advanced echo
(tissue Doppler and speckle tracking radial strain) may be
particularly helpful to differentiate adaptation from HCM
(69–71).
Anterior T-wave inversion (leads V1 to V4) is more
common in black athletes (14.3% of ECGs), compared with
either white athletes or control subjects of either race (65),
and must be distinguished from the T waves of ARVC. Both
black and white athletes have greater RV cavity dimensions
compared with control subjects of the same ethnicity; how-
ever, wall motion abnormalities in combination with RV
dilation is rare, which may aid in distinguishing normal
adaptation from ARVC (65).
Although increased RV and LV volumes are very com-
mon in athletes (58), reduced left ventricular ejection frac-
tion (LVEF) is rare (46,47). However, 11% of healthy
endurance athletes (cyclists) demonstrate mildly reduced
LVEF (68), which must be distinguished from dilated car-
diomyopathy. Improved LVEF with exercise may not be
a helpful clinical tool, because the heart with dilated car-
diomyopathy is capable of some degree of contractile reserve
(75).
The corrected QT interval, longer in athletes compared
with nonathletes (53), requires differentiation from long QT
syndromes, and early repolarization patterns prevalent in
athletic populations should not be confused with Brugada
patterns (76,77) or other potentially lethal conditions (78).
Other cardiac testing. Athletes frequently require ambula-
tory monitoring; difﬁculty with lead adherence during phys-
ical activity or contact with an opponent can impede
monitoring. In such instances, special water-resistant external
devices (79), implantable loop recorders (80), commercial
heart rate monitors (81), or smart shirts (82) may be helpful.
Bruce protocol stress testing, intended to diagnose coronary
artery disease, may be insufﬁcient to reproduce athlete
symptoms. Clinicians are advised to either monitor during the
sporting activity (Fig. 1), or to recreate exercise load and
conditions in the exercise laboratory (83). Upright tilt table
testing is considered unreliable in athletes, perhaps because
of the interaction of high vagal tone with neurocardiogenic
responses (84).
Management of CV conditions. Speciﬁc antihypertensives
(i.e., diuretics or beta-blockers) may be on the World Anti-
Doping Agency prohibited list (85) and are thus not suitable
for certain athletes. Beta-blockade may not be the best
choice due to negative effects on cardiac performance (86).
CV medications, tested in general populations, may not be
able to control cardiac symptoms, or rhythms during ath-
letics, and the tendency of exercise to trigger arrhythmias
may prompt clinicians to ablate re-entrant rhythms or
accessory pathways earlier or without a trial of drug therapy
(87,88) in athletic individuals. The fact that anticoagulants
are contraindicated in contact-sport athletes (24) may in-
ﬂuence choice of valve replacement versus repair in those
wishing to resume contact sports after surgery. Implanted
pacemakers may negatively impact sports performance due
Figure 1 Importance of Proper Choice of Monitoring in Athletes
A 44-year-old man complained of palpitations and dizziness while playing competitive racquetball. A Bruce protocol stress test to 11:50 min was normal at a heart rate of
177 beats/min (A), and failed to reveal the cause of the symptoms. But ambulatory monitoring while playing racquetball revealed ventricular tachycardia at a heart rate
of 144 beats/min (B).
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models (89), prompting the use of custom-made pacemakers
with the ability to achieve and sustain higher heart rates (90).
Implantable cardioverter-deﬁbrillators (ICDs) may not
reliably deﬁbrillate under athletic conditions (91,92), in
which deﬁbrillation thresholds theoretically might be higher
or the ICD may suffer damage to leads or to the device itself.
This hypothesis prompted a recent multinational prospective
registry of the safety of ICDs in sports (93).Thus, signiﬁcant evidence supports that athletes are
“different” from nonathletes from the epidemiological,
physiological, evaluation, and management perspectives,
with signiﬁcant heterogeneity among athlete subgroups.
Combined with the need to consider the effects of CV
conditions and treatments on sports performance and to
incorporate RTP into medical decision making, these dif-
ferences render the athlete a unique CV patient who is
deserving of tailored CV care.
JACC Vol. 63, No. 15, 2014 Lawless et al.
April 22, 2014:1461–72 Sports and Exercise Cardiology in the United States
1465Cardiovascular Specialists as Members of the
Athlete CV Care Team
Athlete CV care team and role of the CV specialist.
Specialized CV care teams have been designed and imple-
mented to manage heart failure (94) and acute coronary syn-
dromes (95)more effectively, but athleteCVcare teams are not
as well-deﬁned. Traditionally, teammedical staff and primary
care physicians (PCPs) perform initial evaluations of athletes
and place CV referrals as necessary (96). But contemporary
models of athlete CV care increasingly require CV specialist
participation to occur earlier and more directly. At the Na-
tional Basketball Association, National Football League, and
Major League Soccer player recruitment combines, local car-
diologists partner with league medical staff to design
and oversee athlete CV testing (personal communication,
E. Dabby [December 2012], J. Provo [September 2013],
A. Tucker [June 2012]). From 30% to 47% of Division 1
NCAA schools perform ECG or echo during pre-
participation evaluation (PPE) (97,98), often requiring CV
specialist interpretation. American high school athletes are
only required to undergo basic PPE (96), but elective CV
screening programs may enlist CV specialist collaboration
(99–101).
Dedicated sports cardiology clinics exist in the United
States (102–107); however, CV specialists in closest proximity
to the athlete, athletic facilities, and teams generally provide
immediate athlete CV care, which allows for efﬁcient evalu-
ation and thereby avoids prolonged absences from practice or
competition and the deleterious effects of detraining (108).
Further care may be provided by a local CV subspecialist (e.g.,
EP), an expert in one of the inherited or acquired diseases
(e.g., HCM), or a sports cardiologist with expertise in a given
sport (e.g., American football). This overall referral pattern
supports that all types of CV specialists acquire at least basic
knowledge in sports and exercise cardiology.
Beyond screening, CV specialists serve athletes for a variety
of other reasons (Table 2). In this capacity, they have
a tremendous opportunity and responsibility to balance
the risk of both underinterpretation and overinterpretation
of ﬁndings and application of technology (109). Underin-
terpretation, or lack of proper treatment, results in exposing
the athlete to unnecessary risk. Similarly, overinterpretationTable 2 Reasons CV Specialists See Athletic Patients
1. Help create and implement cardiac policy.
2. Perform and interpret CV screening tests.
3. Make immediate participation and return-to-play decisions.
4. Determine whether there is a CV cause of symptoms.
5. Evaluate ﬁnding(s) suggestive of underlying CV pathology during non-CV
medical encounters or dedicated pre-participation CV screening.
6. Provide work-up and treatment after nonfatal sudden cardiac arrest.
7. Participation recommendation and exercise prescription with known or
corrected CV disease.
8. Assist in transition from cardiac rehabilitation to higher level of exercise.
CV ¼ cardiovascular.of normal ﬁndings runs the risk of stigmatizing a young
athlete with a diagnosis of heart disease when no disease
actually exists, potentially resulting in a lifetime of perceived
disability; problems with employment, military service, health
insurance, and overall perceptions of health; and resignation
to a lifetime of inactivity.
ACC Sports and Exercise Cardiology Section and annual
summit. In 2011, the American College of Cardiology
(ACC) launched the Section of Sports and Exercise Cardi-
ology. Membership has grown from 150 to over 4,000
members in just 2 short years, indicatingmarked interest from
the CV community to advance the integration of sports and
exercise cardiology into mainstream CV care. The European
Society of Cardiology has had a similar section since 2005
(110). A survey conducted in July 2013 indicated that the
ACC section member cardiologists’ specialties are: general
(77%), imaging (33%), heart failure/cardiomyopathy (17%),
interventional (15%), EP (11%), and pediatrics (9%). More
than 68% of respondents evaluate >10 athletes annually
(Fig. 2A), most often at the high school, collegiate, and rec-
reational levels (Fig. 2B). When asked why they joined theFigure 2
Survey of Members of ACC Sports and
Exercise Cardiology Section (n ¼ 250)
A survey conducted in July 2013 among American College of Cardiology (ACC)
Sports and Exercise Cardiology Section member cardiologists indicated that more
than 68% of respondents evaluate >10 athletes annually (A), most often at the
high school, collegiate, and recreational levels (B).
Table 3 Controversies in Sports and Exercise Cardiology
1. True epidemiology of SCD events
In athletes compared with nonathletes
Among athlete subpopulations
2. CV disease prevalence in athletes compared with nonathletes
3. Best practices in screening for CV disease in athletic populations: none, PPE,
ECG, echo?
4. Best practices to distinguish
Long QT syndrome vs. athlete’s heart?
Brugada syndrome vs. athlete’s heart?
Physiological vs. pathological atrioventricular conduction disturbances?
Physiological vs. pathological early repolarization?
HCM vs. athlete’s heart?
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sports and exercise cardiology,” 55% said to “network with
other cardiology providers with an interest in this subject,”
42% to “assist in athlete ECG or echo screening,” and 41% to
“provide evaluation, participation decisions, and exercise
prescriptions for athletes.”Based on these responses, theACC
Sports and Exercise Cardiology Summit was created. Held
annually, this event features sports cardiology education,
networking opportunities with medical directors of sports
governing bodies, roundtable discussions, and work group
meetings. The section is open to any ACC member with in-
terest in sports and exercise cardiology (111).ARVC vs. athlete’s heart?
DCM vs. athlete’s heart?
5. Utility, efﬁcacy, and proper use of cardiac testing and treatments in athletes
ECG, echo, CMRI, CT
Stress testing
Tilt table
Ambulatory monitoring
ICDs and pacemakers
EP ablations in athletic populations
Antihypertensives, antiarrhythmics, lipid-lowering drugs
6. Is there such a thing as “too much exercise?”
7. Can the differences in ACCF/AHA and ESC recommendations be bridged?
Screening recommendations
Sports participation with known CV disease
8. Can data generated in non-U.S. populations be extrapolated to American
athletes?
9. In the absence of prospective outcome data, can participation guidelines
be less restrictive in those with known CV disease?
10. Can issues of efﬁcacy, cost, and disparities in ECG screening be resolved?
ACCF/AHA ¼ American College of Cardiology/American Heart Association; ARVC ¼ arrhythmogenic
right ventricular cardiomyopathy; CMRI ¼ cardiac magnetic resonance imaging; CT ¼ computed
tomography; CV ¼ cardiovascular; DCM ¼ dilated cardiomyopathy; ECG ¼ electrocardiogram;
echo ¼ echocardiography; ESC ¼ European Society of Cardiology; EP ¼ electrophysiology; HCM ¼
hypertrophic cardiomyopathy; ICD ¼ implantable cardioverter-deﬁbrillator; PPE ¼ pre-participation
evaluation; SCD ¼ sudden cardiac death.Limitations of the Current Diagnostic and
Therapeutic Model
Deﬁciencies in training and consensus documents.
Although athletes clearly require tailored CV care, and CV
specialists serving athletes consider it a priority to be
educated in sports and exercise cardiology, current U.S. CV
training programs fail to provide any organized or required
training in athlete CV care (112,113), and current CV
learning pathways neither deﬁne nor contain core compe-
tencies in this subject matter (114). CV specialists rely on a
few expert consensus documents and conference proceedings
(24,87,88,115–118), primarily based on studies conducted
in nonathletic general populations with known diseases,
knowing that vigorous exercise is a trigger of cardiac events
in these conditions (119,120). In general, documents are
not based on outcome studies in athletic populations
with known diseases. Adherence to these recommendations
is less than optimal (121), perhaps related to the lack of
solid evidence base in athletic populations and/or clinician
opinion that they are too restrictive (122,123).
Lack of “athlete-speciﬁc” knowledge base. Practical
guidelines on how to evaluate clinical symptoms and inter-
pret cardiac testing in athletes are nonexistent, perhaps due
to major knowledge gaps (23), lack of normative data in
large numbers of U.S. athletes at all levels of play (124), or
lack of awareness of athlete CV care as an emerging disci-
pline (76). What is known about cardiac symptoms in
general populations, such as chest pain (125), may not apply
to the athlete. If not studied prospectively in athletes, the
true predictive value of this symptom cannot be known.
Thus, CV specialists evaluate athletes with little evidence-
based guidance or expert consensus.
Gaps in research, science, and quality. To date, there has
not been a single large-scale, prospective, randomized,
controlled CV trial in athletes. Without quality data,
the ability to create true guidelines (supported by a high
level of data) is very limited. Such deﬁciencies result in
multiple controversies in sports and exercise cardiology
(Table 3). As an example, many gaps remain in the CV
screening controversy. Older retrospective studies suggest a
poor sensitivity, 2.5% to 3% (126), of the PPE alone
(history and physical). This ﬁgure may now be as highas 35% to 40% (127), which perhaps questions the need
for ECG. PPE practices in the United States are highly
variable and can suffer from a variety of ﬂaws in design
and execution (128,129). To allow any meaningful com-
parisons between PPE with and without CV screening
tests, improved PPE practices are necessary. As to whether
there is truly any “value added” by ECG and/or echo
regarding outcomes, scholarly ﬁndings are mixed (20,44).
Several ECG interpretation schemes have been proposed
(52,73,77), but no scheme has been prospectively validated
or correlated with CV outcomes, using data derived from
knowledge of underlying structure, in large populations of
U.S. athletes of varying ages, sexes, race/ethnicities, and
sports. Anomalous coronary artery, the second most com-
mon cause of athlete SCD, is not likely to be detected by
ECG (130). Precise sensitivity of echo in detecting origins
of the coronary artery in athletes is not known (131–133),
and may vary according to demographics (e.g., large U.S.
football linemen) or type of anomaly (133). The “ECG
versus no-ECG” debate (134,135) is bound to continue until
uniform acceptable outcome metrics have been established
and a well-designed prospective clinical trial has been con-
ducted to answer the question as to which strategy is superior.
Table 4 New Paradigm: Cardiovascular Care of Athletes
1. Athlete-centered, individualized approach
 Athlete heterogeneity
 Effects of supplements, recreational drugs, and performance-enhancing
agents
 Diagnostic testing: accuracy, interpretation, risk-to-beneﬁt ratio
 Therapies: efﬁcacy, risk-to-beneﬁt ratio, effect on performance
 Return to play: athlete patient preferences vs. risk of sport
 Rules/regulations and rights of: athlete and pertinent governing bodies
 Prescribing proper level of exercise in all
2. Athlete-speciﬁc knowledge base
 Cultivate individual CV specialist core competencies
 Adhere to existing clinical tools
 Consensus documents: awareness of limitations, and consequences
 Gain experience with athletes and athletic culture
 Be aware of legal precedents
3. Clinical tools grounded in sports and exercise cardiology
 Use athlete-speciﬁc protocols for stress tests, ambulatory monitoring
 Develop interpretation schemes to read athlete ECG, echo, CMRI, CT
 Create best practices in sports and exercise cardiology
 Strive toward evidence-based participation guidelines
4. Maintain relevant general or subspecialty cardiology practice
5. Familiarity and collaboration with the overall “athlete healthcare delivery
system”
 Collaborate with athlete care team and their professional organizations and
societies*
 Maintain HIPAA and FERPA compliance (if applicable)
 Communicate clearly and efﬁciently to the athlete care team
 Strive for consensus and consistent messaging
 Assist with transition from any cardiovascular event and/or treatment to
return to play
6. Research, quality, and science
 Promote and perform research
 Develop new registries
 Publish new guidelines, position papers, consensus documents
7. Advocacy
 Promote best practices in sports and exercise cardiology to entire athlete CV
care team
 Encourage creation of athlete CV care teams and centers
 Collaborate with all stakeholders in athlete CV care*
 Assist in responsible legislation that does not discriminate against the
athlete
*Athletic trainers; school nurses; primary care physicians; team physicians; cardiology subspecialty,
sports medicine and primary care professional societies; governing body ofﬁcials; coaches; other
cardiovascular (CV) specialists; and parents.
FERPA ¼ Family Educational Rights and Privacy Act; HIPAA ¼ Health Insurance Portability and
Accountability Act; other abbreviations as in Table 3.
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European and endurance athletes, whereas far less is known
about the U.S. athlete, especially those age 18 years. Some
will possess undiagnosed CV disease and are at risk during
sports participation. More commonly, children and adoles-
cents will carry a known diagnosis of congenital heart disease
(the most common birth defect, 8 of 1,000 live births) (136).
Little to no information has been generated from registries
or research to guide sports participation decisions in this
population (122).
Up to 10% of elite senior athletes report having existing
heart disease or hypertension (137). In this group, sports
participation recommendations may be highly variable, and
outcome data are scarce to nonexistent. Pathological pro-
cesses that promote atherosclerotic vascular disease may
receive comparatively less emphasis in older athletes than
they do among sedentary aging adults, and medications may
be poorly tolerated (138). Effective management of CV
disease with simultaneous preservation of sport performance
may be difﬁcult to balance in the aging athlete and merits
further study.
Traditional funding sources, such as federal agencies or
private foundations, have no mechanism(s) in place that
prioritize athlete work, so investigators may compete with
grants that are designed to study more traditional diseases in
sicker populations, which invariably lead to a better priority
score. In the future, this may change, considering the recent
$30 million donation by the National Football League to the
National Institutes of Health, earmarked for sports medicine
research (139).
Liability, advocacy, and communications. Legal and so-
cioeconomic considerations, such as physician liability con-
cerns, access to care, legislation, governing body rules and
regulations, insurance, scholarships, player union policies,
collective bargaining, and workman’s compensation, may
inﬂuence the CV specialist’s ability to deliver appropriate
athlete CV care (140). Effective interfaces at the national
level are suboptimal. Professional societies present sports
cardiology subject matter at their respective meetings and
meet “as needed” to publish consensus documents, but
organized, periodic, interactive formats in this topical area
among the CV community do not exist.Improving Cardiovascular Care for
Athletes and Exercising Individuals
Care model. To address the aforementioned concerns, we
propose a new paradigm of care for the U.S. athlete and
exercising individual, based upon the fundamentals of
athlete-centered care and a commitment to sports and ex-
ercise cardiology (Table 4).
Education. Essential to the development of a curriculum
in sports and exercise cardiology is the need to deﬁne core
competencies. The 2012 European Society of Cardiology
document provides an exemplary model (76), which can
be adjusted to the way CV specialists train, certify, andpractice in the United States. We suggest that current ACC
CV learning pathways be adapted to incorporate sports and
exercise cardiology competencies within each of the existing
pathways, while creating unique competencies that are
distinct to sports and exercise cardiology. This would result
in an “overlap” between general sports and exercise cardiology
and each subspecialty in cardiology (Fig. 3). Importantly,
consideration must be given to incorporating pediatric sports
and exercise cardiology into the competency model.
Widespread dissemination of and enhanced adherence to
existing clinical tools, such as the 4th PPE monograph (96),
12 AHA elements (141), 36th Bethesda Conference Pro-
ceedings (24), and automated external deﬁbrillators/emer-
gency preparedness protocols (142), should be promoted
and can be achieved through partnering with medical pro-
fessional societies, sports governing bodies, and state legis-
lative policy makers. Current imbalances between the need
Figure 3 Sports and Exercise Cardiology Core Competencies
We suggest that current American College of Cardiology (ACC) cardiovascular (CV)
learning pathways be adapted to incorporate sports and exercise cardiology
competencies within each of the existing pathways, while creating unique com-
petencies that are distinct to sports and exercise cardiology. This results in an
“overlap” between general sports and exercise cardiology and each subspecialty
in cardiology. Importantly, pediatric and adolescent sports and exercise cardiology
must be incorporated into the competency model.
Table 5
Potential Research Directions:
Sports and Exercise Cardiology
1. Epidemiology of cardiac events in athletes
 Detect true prevalence and the clinical relevance of heart diseases
in athletes
 Identify individuals at highest risk
 Develop standardized outcomes metrics for fatal and nonfatal events
 Determine true rate of SCD and SCA in well-deﬁned athletic populations
2. Evaluation
 Determine predictive value of symptoms
 Deﬁne normative data and reference values for ECG, echocardiography, and
CMRI in multiethnic American athletes at different levels (high school
through masters)
 Characterize chamber remodeling in all ages and levels of athletes
 Correlate symptoms and surface ECG with underlying structure
 Elucidate why some athletes remodel and others do not, even among
homogeneous athletic populations
 Prospectively validate cardiac testing in athletes
 Deﬁne which cardiac tests (ambulatory monitoring, stress protocols) lead to
greatest diagnostic yield
 Conduct randomized trials of PPE vs. PPE plus ECG in varying demographic
groups
3. Management
 Determination of efﬁcacy of deﬁbrillation (AEDs and ICDs)
 Create data-driven approach to differentiate pathology from adaptation
i. Cardiomyopathies
ii. Aortic dimension, pulmonary pressure, valvular regurgitation
iii. Long QT, Brugada, early repolarization
 Specify best treatments for asymptomatic WPW and atrial ﬁbrillation
 Identify best way to diagnose and treat anomalous coronary artery
 Correlate changes seen in endurance athletes with long-term outcomes
 Determine risk and/or safe level of exercise in individuals with heart
disease to allow for revision of participation guidelines
AED ¼ automated external deﬁbrillator; SCA ¼ sudden cardiac arrest; WPW ¼ Wolff-Parkinson-
White; other abbreviations as in Table 3.
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deﬁciencies can be corrected by providing low-cost knowl-
edge transfer (online training), adding basic sports and ex-
ercise cardiology education to CV specialist training, and
enhancing programming at annual meetings.
In the short term, the ACC Sports and Exercise Section
plans to pursue the creation of certiﬁcates of competency
indicating that CV specialists have met basic requirements to
interpret athlete CV tests and clear athletes for sports
participation, while at the same time, encouraging and
working with other professional societies to do the same for
PCPs and allied health professionals. For the long term, we
will strive toward an American Board of Internal Medicine–
approved Sports and Exercise Fellowship, with board
certiﬁcation.
Coupled with basic education in sports and exercise car-
diology is the need for CV specialists to obtain practical
experience with athletes and become immersed in the
athletic culture. This can be accomplished through men-
toring opportunities, dedicated sports cardiology clinics,
and encouraging cardiologists to serve on multidisciplinary
athlete CV care teams.
Publications, research, science, and quality. Even if they
are based on expert consensus and have not yet been pro-
spectively validated, there exists a great opportunity to create
practical clinical practice statements to assist CV specialists
and PCPs in delivering uniform athlete CV care. As
ongoing research occurs, statements can be periodically
updated and gradually elevated to the level of true guidelines.
When designing and planning studies, it is crucial that
clinical datasets be tailored to the athlete, and include
age; sex; ethnicity; use of supplements, alcohol, and/orrecreational drugs and performance-enhancing agents;
symptoms; family history; and type and amount of sport,
exercise, and training. Because mortality occurs infrequently
and cardiac disease prevalence may be low, it may be
necessary to deﬁne new outcome measures, perhaps going
beyond the traditional endpoint of mortality, and to be in-
clusive of nontraditional outcomes such as days away from
sports and practice, presence of high-risk conditions,
disqualiﬁcation versus RTP, need to see a CV specialist,
cardiac events, cardiac procedures, cardiac structure and
function, biomarkers, quality of life, iatrogenesis, and the
impact of a potential cardiac issue on the athlete’s mental
health, and performance. Given the growth of the athletic
demographic, their unique needs, and the marginal evidence
base, these challenges should and must be resolved.
Opportunities for research in sports and exercise cardiology
are, at this time, limitless. Based on the areas of known con-
troversy (Table 3), important future research imperatives are
listed in Table 5. The most effective research approaches will
be those that emphasize athlete health and safety, while
simultaneously minimizing unnecessary sport restriction and
inappropriate overtreatment. Clinical algorithms based on
rigorously obtained data need to be developed to address the
symptomatic athlete and positive AHA elements (141),
ambiguities surrounding diagnosis, proper interpretation of
cardiac testing and treatments, and the ECG screening issue.
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tional registries in the form of the National Cardiovascular
Data Registry (143). Its powerful clinical datasets may
provide an opportunity to assess large numbers of athletes
who could not be studied by any other means. Such analyses
are costly, requiring extensive computer capability and a
certain amount of groundwork before studies can be initi-
ated. But there is no longer an impediment to pooling
the data from ECG and echo to determine “normal” in any
particular type of individual. Digital data streams can be
used to establish publicly available normative data.
Liability concerns. Legal precedent has established that
high school or college team medical staff may withhold
student athletes with unacceptable medical risk from
competitive sports and that those clinicians providing CV
care (including CV screening) to athletes must adhere to
published standards of care (140). However, some feel
that, rather than clinicians disqualifying individual athletes,
perhaps it is time for shared decision making between the
athlete patient, family, and the CV specialist, such that an
“individualized approach” be applied to the complex issue
of participation (123). This approach may be more likely to
be adopted in settings where educational institutions,
governing bodies, and professional franchises are not
involved, and the athlete is more autonomous (140).
Advocacy and communications. In view of the crucial need
for research and improved clinical tools, it is increasingly
important to forge collaborative relationships among the key
federal institutes (National Institutes of Health, Centers for
Disease Control, and the Agency for Healthcare Research
and Quality) and lawmakers, as well as sports organizations
and alliances (National Athletic Trainers’ Association,
NCAA, U.S. Olympic Committee, National Federation of
State High School Associations, Youth Sports Safety Alli-
ance and Joint Commission on Sports Safety) to create
knowledge that will better inform clinical decision making,
public policy, and reimbursement. Linked to these broad
objectives is a need to disseminate principles of sports and
exercise cardiology to CV caregivers, coaches, administrators,
legislators, and athlete patients (and parents).
Conclusions
The growing athletic population demonstrates a unique need
for highly tailored CV care, known as sports and exercise
cardiology. Dedicated to this new paradigm of athlete CV
care, the ACC Sports and Exercise Cardiology Council and
Section will devote its collective energy and effort toward
achieving the goals outlined here. By doing so, we believe we
have the ability to serve the greater athletic community and
our nation by allowing the safest participation in sports and
physical activity for all individuals who seek this lifestyle.
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